Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Developmental Therapeutics Program (DTP)
Contact DTP
Show menu
Search this site
Last Updated: 10/16/20

Marc Ernstoff, MD

Marc Ernstoff, MD

Chief

ImmunoOncology Branch

Dr. Marc Ernstoff joined the NCI Division of Cancer Treatment and Diagnosis, Developmental Therapy Program in 2020 as Medical Officer and the new Chief of the ImmunoOncology Branch. He has over 40 years experience in studying the immunobiology of human cancer and the development of new immune therapies. Dr. Ernstoff did his Medical Oncology and cancer immunology training at Yale University where he stayed as an Assistant Professor of Medicine prior to joining the medical oncology and translational immunotherapy program at the University of Pittsburgh Cancer Institute. Much of his career was spent at Dartmouth College’s Geisel School of Medicine where he was Section Chief of Hematology/Oncology and the Deputy Director of the Norris Cotton Cancer Center. He was also the Director of the Melanoma Program at the Cleveland Clinic. Prior to joining NCI, he was Professor and Chair, Department of Medicine, Senior Vice President for Clinical Investigation, The Katherine Anne Gioia Chair of Medicine at Roswell Park Comprehensive Cancer Center. He published over 250 original research manuscripts in the areas of renal cell cancer, melanoma and immune therapy strategies including cytokine therapies, dendritic cell vaccines, immune checkpoint inhibition, targeted therapies and ex vivo expanded effector cells for adoptive transfer.

About the Branch Chief

Dr. Marc Ernstoff Dr. Marc Ernstoff joined the NCI Division of Cancer Treatment and Diagnosis, Developmental Therapy Program in 2020 as Medical Officer and the new Chief of the ImmunoOncology Branch. He has over 40 years experience in studying the immunobiology of human cancer and the development of new immune therapies. More…